Aetos Biologics

Aetos Biologics is a biopharmaceutical company specializing in the development and commercialization of high-quality biosimilar products. Acquired by Amneal Pharmaceuticals in 2018, the company serves as a core component of Amneal's biologics strategy, focusing on complex monoclonal antibodies and recombinant proteins. Aetos targets therapeutic areas with high unmet needs and significant healthcare costs, particularly oncology and immunology. Their portfolio includes several FDA-approved biosimilars, such as Alymsys (bevacizumab-maly), Releuko (filgrastim-ayow), and Fylnetra (pegfilgrastim-pbbk). The company utilizes advanced analytical characterization and manufacturing processes to ensure their biosimilars meet rigorous regulatory standards for safety and efficacy. Through its integration with Amneal, Aetos Biologics aims to expand patient access to life-changing biologic therapies globally.